Kala Bio Q2 EPS $(3.16) Beats $(4.40) Estimate
Portfolio Pulse from Benzinga Newsdesk
Kala Bio (NASDAQ:KALA) reported a Q2 EPS of $(3.16), beating the analyst consensus estimate of $(4.40) by 28.18%. This represents a 27.52% improvement over the same period last year.
August 06, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kala Bio reported a Q2 EPS of $(3.16), significantly beating the analyst consensus estimate of $(4.40) and showing a 27.52% improvement over the same period last year.
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact Kala Bio's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100